



**KANEKA**

The Dreamology Company  
—Make your dreams come true—

(Stock Code: 4118)

To Our Shareholders

**Interim Report for  
the 101st Business Period**

From April 1 to September 30, 2024

**KANEKA CORPORATION**



# KANEKA thinks “Wellness First”.

Kaneka contributes to the sustainability of the earth,  
develops its business in a “wellness-first” direction, energizes people,  
adds vibrancy to business, and helps build a happier society.

To make the world more wellness-first.

Kaneka takes an innovative approach to science,  
and seeks to fulfil people’s dreams  
by offering a wide variety of solutions.

## Sustainable Solutions for an Evolving World



### CONTENTS

|   |   |   |    |                                    |    |
|---|---|---|----|------------------------------------|----|
| To Our Shareholders .....                             | 2 | Feature .....                           | 7  | Corporate Data .....               | 13 |
| Highlights of Consolidated Business Performance ..... | 3 | Topics .....                            | 9  | Information for Shareholders ..... | 14 |
| Business Performance by Segment .....                 | 4 | Consolidated Financial Statements ..... | 12 |                                    |    |

## To Our Shareholders



President and Representative Director



Kazuhiko Fujii

Thank you for your continued support and interest in the Kaneka Group. I would like to explain the results for the first half of fiscal 2024 (April 1, to September 30, 2024) and the outlook for the future.

### ➤ State of Global Economy – Ongoing economic stagnation, with the outlook remaining uncertain –

While the pace of economic recovery was still slow in Japan, domestic demand in China remained sluggish. In the meantime, the trend of economic downturn continued in Europe. Although consumption remained firm in the U.S., there have been concerns over a potential slowdown. With the political climate becoming uncertain in the U.S. and Japan, coupled with growing geopolitical risks such as the worsening Middle East crisis, the outlook of the global economy is currently clouded by uncertainties.

### ➤ Kaneka Group’s Business Performance – Sales and profits increased, maintaining momentum in 2Q (July 1 to September 30, 2024)

Under these circumstances, Kaneka Group’s business performance for the first six months of the fiscal year ending March 31, 2025 was as follows. Consolidated net sales were ¥395,963 million (up 7.0% year-on-year), operating income was ¥19,101 million (up 51.5% year-on-year), ordinary income was ¥14,391 million (up 13.0% year-on-year), and net income attributable to owners of parent was ¥10,162 million (up 14.2% year-on-year).

Under the uncertain demand environment, the Group recorded year-on-year increases across key indicators, including net sales, operating income, ordinary income, and net income attributable to owners of parent. Overall, the Group maintained strong momentum, which had been continued since 1Q (April 1 to June 30, 2024).

Material Solutions Unit, Quality of Life (QoL) Solutions Unit, and Nutrition Solutions Unit recorded a significant year-on-year increase in profits. On the other hand, however, Health Care Solutions Unit reported a year-on-year decrease in profits as some shipments are postponed to 4Q (January 1 to March 31, 2025) in the Pharma business due to shipment adjustments, despite continued strong performance of the Medical business. The growth momentum of all solutions units, including Health Care, is expected to become stronger as sales in the Pharma business is likely to pick up. For these reasons, we can expect quarterly operating income to exceed ¥10 billion in 4Q.

With progress being made in shifting to leading-edge businesses, (Modified Silicone polymers, E & I Technology, PV & Energy management, Medical, Pharma, and Supplemental Nutrition), we are steadily making strides forward in our portfolio transformation.

### ➤ Consolidated Business Forecasts


The global GDP growth forecast announced by the IMF in October remains low at 3.2% for both 2024 and 2025. The situation is likely to be highly uncertain due to fluctuations in financial and foreign exchange markets, as well as to increasing geopolitical risks, such as in the Middle East and Ukraine.

Under such circumstances, we will expand the line-up of differentiating technologies that are unique to Kaneka to speed up a shift in our business portfolio. In the second half of fiscal 2024, we will work to continue the strong momentum, which have continued since 1Q, as a whole.


We have decided to set the interim dividend at ¥60 per share. In closing, I sincerely request your continued support for the Kaneka Group.

## Highlights of Consolidated Business Performance (Transition / Result of the first half and forecast of the fiscal year 2024)


### ▶ Net Sales




### ▶ Operating Income



### ▶ Ordinary Income



### ▶ Net Income Attributable to Owners of Parent




## Business Performance by Segment (The first half of the fiscal 2024)

### ▶ Net Sales and Operating Income by Segment


(Billions of Yen)

|                                       | Net sales  |                           | Operating income                                       |                           |
|---------------------------------------|--|---------------------------|--|---------------------------|
|                                       | The first half of the fiscal 2024 (101 <sup>st</sup> ) | Difference (year-on-year) | The first half of the fiscal 2024 (101 <sup>st</sup> ) | Difference (year-on-year) |
| <b>Material Solutions Unit</b>        | 169.9  | 13.4<br>8.6%              | 16.1   | 3.9<br>32.6%              |
| <b>Quality of Life Solutions Unit</b> | 93.4   | 8.7<br>10.2%              | 9.6  | 2.5<br>34.5%              |
| <b>Health Care Solutions Unit</b>     | 36.4   | 0.2<br>0.6%               | 5.4  | (0.4)<br>(7.6%)           |
| <b>Nutrition Solutions Unit</b>       | 95.8   | 3.8<br>4.1%               | 6.4  | 1.9<br>40.9%              |
| Others                                | 0.4  | (0.2)<br>(32.0%)          | 0.2  | (0.2)<br>(54.3%)          |
| Adjustment                            | —  | —                         | (18.6)   | (1.1)<br>(—)              |
| <b>Total</b>                          | <b>396.0</b>   | <b>25.8<br/>7.0%</b>      | <b>19.1</b>  | <b>6.5<br/>51.5%</b>      |

### ▶ Composition Ratio of Net Sales by Segment



### ▶ Composition Ratio of Net Sales by Region



\*The ratio of the graph is rounded off to the nearest display unit.

Please see the next page for details of each Solutions Unit. ▶



# Business Performance by Segment

## Earthology Chemical Solution

We bring innovation to lifestyles and the environment by harnessing the unlimited potential of chemical materials to help communities achieve sustainability.

### Material Solutions Unit

To support the advancement of life and the environment by drawing out the richness of the materials  
Material Value Creator

Sales and profits increased as the strong growth momentum continued in Modifiers and Modified Silicone polymers. We forecast full-year profit growth.

- For Vinyls and Chlor-Alkali, operating income was on par with the same period last year. The business performance is expected to recover up in 4Q, contributed by the price revision for PVC carried out in Japan.
- For Modifiers, sales increased at all locations as we succeeded in maintaining our competitiveness, which had recovered in the previous fiscal year. The sales of products for non-PVC use and epoxy masterbatch (MX), which have differentiation capabilities, expanded steadily, contributing to an increase in earnings.
- In Modified Silicone polymers, our facilities in Belgium with increased production capacity started operations smoothly. As with the first half of this fiscal year (April 1 to September 30, 2024, "1H"), the momentum of sales expansion and higher earnings is likely to continue in the second half of this year (October 1, 2024 to March 31, 2025, "2H").
- For Green Planet™, progress has been made on our efforts to achieve large-scale product adoption by major brand holders around the world. As evident in the product starting to be adopted for a foam cushioning material for home electrical appliances and automobiles, there has been further increasing interest in Green Planet™. We will steadily proceed with the launch of a demonstration plant for the mass production of Green Planet™.

### Quality of Life Solutions Unit

To produce the leading edge of the enhancement of the quality of life through the power of materials  
Quality of Life Pathfinder

High earnings posted by E&I Technology contributed to significant increases in both sales and profits overall. Strong momentum in E&I Technology is expected to continue in 2H.

- For Foam & Residential Techs, performance was adversely affected by decreased demand in the automobile sector and the domestic agricultural and fishery and construction sectors, and higher raw material prices. With progress expected to be made in the price revision in 2H, full-year earnings are projected to recover up to the level of the previous fiscal year.
- For E & I Technology, profits increased significantly year-on-year thanks to the high-level sales of polyimide films and acrylic resins. Earnings are likely to remain high in 2H, boosted by strong demand for smartphones and TVs.
- For PV & Energy management, the sales of high-efficiency photovoltaic modules for residential use steadily increased. We will speed up our efforts to expand and enhance the line-up of high-value-added products by increasing the sales of products for zero-energy building (ZEB), in which walls and windows generate electricity, as well as by stepping up research and development of perovskite.
- For Performance Fibers, profits increased year-on-year, owing to a steady recovery in the sales of hair accessory products. Despite the persistent high inflation and currency depreciation, combined with continued political uncertainties in African countries, we are planning to create demand by launching new products.

## Active Human Life Solution

By adopting a unified approach to food and medicine that is defined by a focus on chemistry, we provide innovative solutions that empower people to live healthier lives.

### Health Care Solutions Unit

To create a world where advanced medical means are available to as many people as possible  
Medical Edge Explorer

Further progress being made in introducing new products and expanding sales in Medical; temporary shipment adjustments in Pharma. We expect full-year earnings to expand in the entire unit.

- For Medical, a new plant for blood purification devices in Hokkaido (Tomato Manufacturing Site) has started operations smoothly. Meanwhile, the sales of both blood purification devices and catheters have expanded steadily. Recently, we have decided to construct a new catheter plant at said manufacturing site. With the new plant, we aim to respond to increasing demand worldwide, thereby achieving exponential growth in business operations.
- For Pharma, the sales of pharmaceuticals declined as some shipments are postponed to 4Q due to shipment adjustments. Although the impact of the shipment adjustments is expected to remain in 3Q (October 1 to December 31, 2024), the business is likely to post a substantial year-on-year increase in profits in 4Q, driven by the concentration of shipments for newly acquired large projects.

### Nutrition Solutions Unit

To re-innovate food and health  
Nutrition Value Chain Innovator

Continued solid performance of both Supplemental Nutrition and Foods & Agris; significant increases in both sales and profits. With the favorable performance expected to be maintained in 2H, we are projecting a substantial year-on-year increase in full-year profits.

- For Supplemental Nutrition, in response to a reactionary decline in the sales of the active form of coenzyme Q10 in the U.S. following concentrated shipments in 1Q, we faced adjustments to inventory by customers in 2Q. As sales are expected to further increase in global markets in 2H, earnings is likely to grow steadily.
- For Foods & Agris, progress has been made in shifting to high-value-added products and improving profit margin, resulting in the continued momentum of strong profit growth. For "Business to Consumer" business, the sales of unique and distinctive high-value-added products have been expanding mainly attributable to the expansion of the product line-up of "Watashi no Chikara (My Energy)™ - Q10 Yogurt" and other new foods with function claims, the sales expansion of "Kaneka Q10 Fruit Gummies," and the market launch of organic dairy products. The shift to high-value-added products and the sales expansion of newly released products are likely to continue progressing in 2H, maintaining favorable performance.





**Feature: Think Global, Act Local**

## A Global Network Rooted in Local Communities that Overcomes Cultural Differences

– Kaneka marks 40th year in the Americas and 50th year in Europe in 2024 thanks to your support –

Driven by a strong desire to bring its unique technology and products to every corner of the world, Kaneka expanded into Belgium and then the US during the 1970s and 80s. Our goal is to become a company with a global presence by seamlessly providing impactful solutions to customers worldwide in a timely manner to protect people’s lives and solve social issues.



### Kaneka North America LLC (Kaneka North America) Celebrates 40th Anniversary

In 1982, Kaneka established Kaneka Texas Corporation in Texas, US. Two years later, in 1984, the company started operation of its first Modifier unit. Since then, Kaneka North America has supplied a host of unique technologies and products in the Americas, including APICAL™, chlorinated polyvinyl chloride (CPVC) and the active form of coenzyme Q10 (CoQ10), and taken on the localized production of Modified Silicone polymers. In June this year, the company marked the 40th anniversary of the first modifier’s startup, holding various commemorative events.

These included a courtesy visit to the Mayor of Pasadena, a local municipality that has supported the company, and donations to local charitable organizations. The company also held a commemorative party for 400 employees, alumni and their families to express its gratitude and send a message for the future, with many friends and colleagues expressing great hopes for the company in the years to come.




Visit to the Mayor of Pasadena



Group photo in front of 40th anniversary commemorative statue

## Global Network Strategies

Kaneka’s regional headquarters take the lead in drawing up and executing growth strategies with scale and speed. Tapping into the strengths of our Group companies with their local characteristics enables us to create business models matched to market needs. Going forward, we aim to continue accelerating business development that makes much closer connection with the local community.



### Kaneka Belgium N.V. (Kaneka Belgium) Celebrates 50th Anniversary

Kaneka was one of the first Japanese companies to enter the Belgian market, establishing Kaneka Belgium and launching full-scale operations in 1974 with the startup of a modifier plant. Since then, the company has increased modifier production capacity for the European market, while also starting and progressively ramping up production of polyolefin foam (Eperan™) and Modified Silicone polymers. The Belgian business became the foundation for Kaneka’s later global expansion into the Americas and Asia.

In October 2024, Kaneka Belgium marked its 50th anniversary, making courtesy visits to local authorities to express its gratitude for their support since the company’s establishment and hosting a stakeholder event to celebrate the milestone. The event was attended by around 150 guests, including Princess Astrid of Belgium, the Japanese Ambassador to the EU and the Governor of Antwerp Province.

The company also hosted a commemorative ceremony with 700 employees, alumni and their families and held local community exchange events, creating unforgettable experiences that strengthened the bond between Kaneka and its internal and external stakeholders.



Visit to the Mayor of Westerlo



Chatting at the 50th anniversary ceremony venue



## New Advanced Medical Device Plant Construction Completed in Hokkaido

– From Tomatoh, “Kaneka, the Dream Factory” –



New Tomatoh Manufacturing Site

### Kaneka’s First New Domestic Business Location in 54 Years

In August 2024, Kaneka opened the Tomatoh Manufacturing Site in the Tomakomai Tobu Area of Hokkaido. The Tomatoh Manufacturing Site is Kaneka’s fifth domestic plant and the first to be opened in 54 years.

The opening ceremony was attended by 160 people, including Naomichi Suzuki, Governor of Hokkaido, and Atsushi Kimura, Deputy Mayor of Tomakomai City. The ceremony was followed by a commemorative party at a hotel in Tomakomai to express Kaneka’s gratitude to all those who supported the plant’s opening.



Ribbon-cutting ceremony



Thank you speech at the commemorative party

### Smart Factory and Zero Energy Factory

The Tomatoh Manufacturing Site is a “smart factory” that uses advanced technologies such as AI and robotics to achieve “field operation zero” (zero operator on the factory floor), or fully automated production lines. The goal is also to realize a “zero energy factory” utilizing our photovoltaic modules.

Following the opening of the plant, which makes blood purification devices, we made the decision in November to construct a new catheter plant at Tomatoh manufacturing site. We aim to expand the Medical business by supplying competitive products globally from the Tomatoh region, which has excellent land, sea and air links.

Based on our mission of “KANEKA thinks ‘Wellness First,’” we will realize a world where advanced medical care is accessible to everyone and where science contributes to the innovation of the global environment and our daily lives.



Automated processing using robots

A video of the Tomatoh Manufacturing Site is now available on Kaneka’s website (Japanese)



## Steady Stream of New Food Products with Function Claims, Focused on Deliciousness and Health

– Introducing the Active Form of Coenzyme Q10 into the Food Space –

In May 2024, we launched “Watashi no Chikara (My Energy)™ - Q10 Yogurt Brain Care Drink Type” and in September we launched the cup type as popular new additions to our lineup of products containing the active form of coenzyme Q10, a proprietary Kaneka ingredient. Also in September, we began selling “Watashi no Chikara (My Energy)™ - Kaneka Q10™ Fruit Gummies” which support wellness from within the body to address both skin health and stress. The product was developed in response to reports that the active form of coenzyme Q10 “helps maintain the skin moisture of healthy women.” Also, in November, we launched “Watashi no Chikara (My Energy)™ - Kaneka Q10™ Moist Skin Care & Stress Drink Type,” which addresses concerns about stress and skin moisture with new functionality to “improve temporary stress” and “maintain moisture.”

We are further working to increase the appeal of our active form of coenzyme Q10 ingredient with other new products, such as a drink jointly developed with hot yoga studio LAVA called “NightVeil™” with functional claims that address both skin and sleep.

Based on our management vision of “KANEKA thinks ‘Wellness First,’” we are rolling out products focused on delicious flavor and health. Going forward, we will continue to contribute to people’s health and rich dietary lives by further enriching our lineup of health products that contain Kaneka’s nutritional supplement ingredients.



Kaneka Ambassador Kurara Chibana at product launch



Watashi no Chikara (My Energy)™ Q10 Yogurt Moist Skin Care & Stress Drink Type

Watashi no Chikara (My Energy)™ Q10 Yogurt Brain Care Drink Type (left) Cup Type (right)

NightVeil™

Watashi no Chikara (My Energy)™ Kaneka Q10™ Fruit Gummies Juicy Peach Flavor



## Creating a New Kaneka Culture:

### – Initiatives at the Takasago Manufacturing Site, Kaneka’s Production Base “Mother Port” –

#### Wellness Initiatives

To realize “Wellness First Health Management,” we are promoting the creation of healthy workplaces where employees are energetic and motivated. Our goal is to create a new work culture.

In 2022, we opened the “KANEKA Wellness Center Kaze no Mori™” as a symbol of the Group’s health management. In 2023 we completed a new main gate to help employees switch their mind to work, and a centralized changing facility to ensure employees’ health and safety awareness. A construction of new office building was also completed in August this year. The new building will be used to 1) realize employee wellness and smart work, 2) raise awareness and generate ideas through diverse communication, and 3) provide strategic functions for manufacturing sites, including as a crisis management center.



New office design with OLED lighting and solar power



Free address system to invigorate communication across departmental lines

#### Final Step

As the final step to complete the facility, Kaneka made the decision in November to construct a new welfare facility. The building will have a cafeteria, store and a venue to showcase Kaneka’s businesses and activities, as well as a lounge and terrace area. The building will be used as a place to prepare the mind and body and cultivate connections between employees that trigger “chemical reactions,” creating a space to “Meet, Connect and Inspire.”

We plan to transform the new facility, including the new welfare building, into a place that opens the door to “Limitless Adventure,” reshaping the Takasago Manufacturing Site’s culture as a global center.



CG image of the completed new welfare building

## Consolidated Financial Statements

### ▶ Semi-annual Consolidated Balance Sheets (Summary) (Billions of Yen)

| Accounts title                   | 101st                    | 100th                |
|----------------------------------|--------------------------|----------------------|
|                                  | As of September 30, 2024 | As of March 31, 2024 |
| <b>Assets</b>                    |                          |                      |
| Current assets                   | 415.3                    | 428.9                |
| Noncurrent assets                | 442.2                    | 441.3                |
| Total assets                     | 857.5                    | 870.2                |
| <b>Liabilities</b>               |                          |                      |
| Current liabilities              | 285.8                    | 291.7                |
| Noncurrent liabilities           | 96.8                     | 104.2                |
| Total Liabilities                | 382.6                    | 395.8                |
| <b>Net assets</b>                |                          |                      |
| Shareholders’ equity             | 389.4                    | 387.4                |
| Others                           | 85.5                     | 87.0                 |
| Total net assets                 | 474.9                    | 474.4                |
| Total liabilities and net assets | 857.5                    | 870.2                |

#### Point

- As of September 30, 2024, **total assets** were ¥857.5 billion, down ¥12.7 billion from the previous fiscal year-end. This is mainly due to a decrease in notes and accounts receivable-trade.
- **Liabilities** totaled ¥382.6 billion, down ¥13.2 billion, primarily reflecting a decrease in notes and accounts payable-trade.
- **Net assets** were ¥474.9 billion, up ¥0.5 billion, owing chiefly to an increase in retained earnings, which was partially offset by dividends paid and an increase in treasury stock. Equity ratio was 53.0%.

#### Point

- **Net sales** increased by ¥25.8 billion, or 7.0%, year-on-year.
- **Operating income** increased by ¥6.5 billion, or 51.5%, year-on-year.
- **Ordinary income** increased by ¥1.7 billion, or 13.0%, year-on-year
- **Net income attributable to owners of parent** increased by ¥1.3 billion, or 14.2%, year-on-year

#### Point

- In the first six months ended September 30, 2024, net cash provided by **operating activities** was ¥23.0 billion, mainly due to the recording of income before taxes and depreciation and amortization.
  - Net cash used in **investing activities** amounted to ¥30.4 billion, owing primarily to purchase of property, plant and equipment.
  - Net cash provided by **financing activities** was ¥1.6 billion due to an increase in loans payable, which was partially offset by redemption of bonds and purchase of treasury stock.
- As a result, **cash and cash equivalents as of September 30, 2024** totaled ¥38.1 billion.

### ▶ Semi-annual Consolidated Statement of Income (Summary) (Billions of Yen)

| Accounts title                              | 101st                                    | 100th                                    |
|---|--|--|
|   | From April 1, 2024 to September 30, 2024 | From April 1, 2023 to September 30, 2023 |
| Net sales                                   | 396.0                                    | 370.1                                    |
| Operating income                            | 19.1                                     | 12.6                                     |
| Ordinary income                             | 14.4                                     | 12.7                                     |
| Income before income taxes                  | 15.6                                     | 14.4                                     |
| Net income attributable to owners of parent | 10.2                                     | 8.9                                      |

### ▶ Semi-annual Consolidated Statement of Cash Flows (Summary) (Billions of Yen)

| Accounts title                                      | 101st                                    | 100th                                    |
|---|--|--|
|   | From April 1, 2024 to September 30, 2024 | From April 1, 2023 to September 30, 2023 |
| Net cash provided by (used in) operating activities | 23.0                                     | 24.0                                     |
| Net cash provided by (used in) investing activities | (30.4)                                   | (30.6)                                   |
| Net cash provided by (used in) financing activities | 1.6                                      | 9.9                                      |
| Cash and cash equivalents at end of period          | 38.1                                     | 44.9                                     |

\* If you would like to find out more, please visit Kaneka’s website.



# Corporate Data

(As of September 30, 2024)

## ▶ Corporate Profile

**Name** KANEKA CORPORATION

**Tokyo Head Office** 1-12-32, Akasaka, Minato-ku, Tokyo 107-6028, Japan  
TEL: +81-3-5574-8000

**Osaka Head Office** 2-3-18, Nakanoshima, Kita-ku, Osaka 530-8288, Japan  
TEL: +81-6-6226-5050

**Date of Establishment** September 1, 1949

**Paid-in Capital** 33,046 million yen

**Website** <https://www.kaneka.co.jp/>

## ▶ Members of the Board and Audit & Supervisory Board Members

|   |                     |
|---|---------------------|
| Chairman of the Board (Representative Director) | Kimikazu Sugawara   |
| President (Representative Director)             | Kazuhiko Fujii      |
| Member of the Board, Executive Vice President   | Shinichiro Kametaka |
| Member of the Board, Executive Vice President   | Mamoru Kadokura     |
| Managing Executive Officer                      | Katsunobu Doro      |
| Member of the Board, Managing Executive Officer | Jun Enoki           |
| Managing Executive Officer                      | Toshio Komori       |
| Managing Executive Officer                      | Masaaki Kimura      |
| Member of the Board (outside)                   | Mamoru Mohri        |
| Member of the Board (outside)                   | Jun Yokota          |
| Member of the Board (outside)                   | Yuko Sasakawa       |
| Member of the Board (outside)                   | Hiroshi Miyake      |
| Audit & Supervisory Board member (standing)     | Masami Kishine      |
| Audit & Supervisory Board member (standing)     | Shinobu Ishihara    |
| Audit & Supervisory Board member (outside)      | Hiroshi Fujiwara    |
| Audit & Supervisory Board member (outside)      | Yasuhiro Uozumi     |

## ▶ Stock Information

Total number of authorized shares ..... 150,000,000 shares

Number of shares issued and outstanding ..... 66,000,000 shares

Number of shareholders ..... 25,880 shareholders


Average number of shares per shareholder ..... 2,550 shares

## ▶ Major Shareholders

| Name of Shareholders                                | Share Units Owned (thousand shares) | Percentage of Total Shares Issued (%) |
|---|-------------------------------------|---------------------------------------|
| The Master Trust Bank of Japan, Ltd.(Trust Account) | 7,258                               | 11.53                                 |
| Nippon Life Insurance Company                       | 3,114                               | 4.95                                  |
| Sumitomo Mitsui Banking Corporation                 | 3,091                               | 4.91                                  |
| Meiji Yasuda Life Insurance Company                 | 2,825                               | 4.49                                  |
| Custody Bank of Japan, Ltd. (Trust Account)         | 2,613                               | 4.15                                  |
| MUFG Bank, Ltd.                                     | 2,308                               | 3.67                                  |
| Mitsui Sumitomo Insurance Company, Limited          | 2,104                               | 3.34                                  |
| BNYMSANV AS AGENT/CLIENTS LUX UCITS NON TREATY 1    | 1,626                               | 2.58                                  |
| Kaneka Business Partner Shareholding Association    | 1,365                               | 2.17                                  |
| Kaneka Employee Stock Ownership Plan                | 1,280                               | 2.03                                  |

Notes: 1. The numbers of Share Units Owned are rounded down to thousands of shares.  
2. The Percentage of Total Shares Issued is calculated by using deducting number of treasury shares from Number of Shares Issued and Outstanding and rounded to two decimal places.  
3. In addition to the above list, the Company maintains 3,066 thousand shares of treasury stock.

## ▶ Shareholder Composition



Notes: 1. The numbers of Share are rounded down to thousand of shares.  
2. The numbers of Percentage are rounded to one decimal places.

# Information for Shareholders

## ▶ Kaneka's Website

Disclosures such as integrated reports and the latest news releases are available for viewing on Kaneka's website. We will continue to enhance the website's content and to provide timely and appropriate disclosure.

### ▼ IR Information

View Kaneka's integrated report on the official website.




## ▶ Memo for Shareholders

|  |   |
|--|---|
| Fiscal Year  | April 1 to March 31   |
| Ordinary Shareholders Meeting  | Held in June  |
| Record Dates   | Ordinary Shareholders Meeting : March 31<br>Year-end dividend : March 31<br>Interim dividend : September 30 |
| Transfer agent and share registrar and account management institution for special accounts | Mitsubishi UFJ Trust and Banking Corporation  |

Cover art illustration: Asae Soya  
• Title: Topia  
• Creation date: 2022

## ▶ How to Receive Dividends

Dividends can be received in three ways. Methods ② and ③ below allow shareholders to receive dividends on the same day as the date of dividend distribution. Furthermore, **shareholders may no longer receive dividends for which 3 full years have passed since the date of dividend distribution.** Therefore, please be sure to make use of account transfers for dividends.



## Contact

For inquiries about the account transfer of dividends, including confirmation of your current dividend payment method or related changes, please contact your securities company (account managing institution).

## Inquiries for Procedures

Notes: 1. Procedures such as changes of shareholder's address, requests to acquire shares, and so forth, are to be handled in principle by the account managing institution (securities company, etc.) where the shareholder has an account. Please refer such requests to the securities company, etc., where you have opened an account.  
2. For related to shares registered in special accounts, please inquire to the special account managing institution on the left, Mitsubishi UFJ Trust and Banking Corporation. Such enquiries can be received at Mitsubishi Trust and Banking Corporation Head Office and branches.  
3. Unclaimed dividends will be paid at the Mitsubishi UFJ Trust and Banking Head Office and branches.